Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …

Small cell lung cancer (SCLC) remains one of the most lethal malignancies and a major
health riddle. The therapeutic options are limited. The combination of etoposide or irinotecan …

Purpose: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high
relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor …

Abstract Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor
activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb …

Background Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies
and its prognosis is dismal. Although early studies have shown promising clinical activity of …

Introduction This open-label, phase 1–2 study evaluated the safety and efficacy of
rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune …

Introduction This first-time-in-humans study assessed the safety, pharmacokinetics (PK),
pharmacodynamics (PD), and clinical activity of GSK2879552 in patients with relapsed or …

Introduction Lung cancer has a poor prognosis that varies internationally when assessed by
the two major histological subgroups (non-small cell (NSCLC) and small cell (SCLC)) …

Small cell lung cancer (SCLC) represents 15% of lung cancers and is characterized by early
dissemination, development of chemoresistance and a poor prognosis. A host of diverse …

Objectives The neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR)
have been proved to affect the prognosis of various types of cancers. However, the …